Illumina has introduced the TruSeq Amplicon - Cancer Panel, a multiplexed panel that the company says will allow researchers to accurately sequence hundreds of the most relevant cancer loci, even in difficult samples such as formalin-fixed, paraffin embedded (FFPE) tumor samples.
The TruSeq Amplicon is capable of detecting mutations below 5% frequency and provides quality data across many samples, all in one experiment, said the company.
Illumina Genomics Solutions Business senior vice president and general manager Christian Henry said the TruSeq Amplicon – Cancer Panel is an important advancement for clinical researchers, enabling them to conduct in a matter of days cancer studies that were previously impractical.
"Combined with the accuracy, speed, and ease of use of the MiSeq personal sequencer, this powerful new solution will help unlock millions of FFPE samples as our customers seek to elucidate the biological complexity of cancer," Henry said.
The multiplexed panel also delivers confidence and simplicity with up front FFPE sample quality control, built-in assay controls, and on-instrument automated analysis for variant calling.